During the last three months, 8 analysts shared their evaluations of Lexicon Pharmaceuticals (NASDAQ:LXRX), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 8 | 0 | 0 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 2 | 0 | 0 | 0 | 0 |
2M Ago | 3 | 0 | 0 | 0 | 0 |
3M Ago | 2 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $10.0, a high estimate of $10.00, and a low estimate of $10.00. No alteration is observed as the current average remains at the previous average price target.
A comprehensive examination of how financial experts perceive Lexicon Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $10.00 | $10.00 |
Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $10.00 | $10.00 |
Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $10.00 | $10.00 |
Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $10.00 | $10.00 |
Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $10.00 | $10.00 |
Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $10.00 | $10.00 |
Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $10.00 | $10.00 |
Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $10.00 | $10.00 |
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Lexicon Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Lexicon Pharmaceuticals analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Lexicon Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 419.56%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Lexicon Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -3244.02%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -20.21%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Lexicon Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -13.52%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Lexicon Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.42.
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.